[Effects of gomisin A, a lignan component of Schizandra fruits, on experimental liver injuries and liver microsomal drug-metabolizing enzymes].
Effects of oral administration of gomisin A, one of the components isolated from Schizandra fruits, on liver injuries induced by CCl4, d-galactosamine and dl-ethionine and on liver microsomal drug-metabolizing enzyme activities were investigated. Gomisin A suppressed the increase of serum transaminase activities and the appearances of histological changes such as degeneration and necrosis of hepatocyte, inflammatory cell infiltration and fatty deposition in each type of liver injury. The repeated administration of gomisin A (30 or 100 mg/kg, p.o., daily for 4 days) induced an apparent increase of liver weight in liver-injured and normal rats. Gomisin A decreased serum triglyceride and lipid contents of the liver in biochemical studies. Increases of microsomal cytochrome b5 and P-450, elevations of NADPH cytochrome C reductase, aminopyrine N-demethylase and 7-ethoxycoumarin O-deethylase activities and decrease of 3,4-benzo(a)pyrene hydroxylase activity per cytochrome P-450 were observed after the administration of gomisin A. In addition, gomisin A was found to enhance the incorporation of 14C-phenylalanine into liver protein and to shorten the hexobarbital-induced sleeping time. These changes caused by gomisin A were similar to those by phenobarbital. However, gomisin A is distinctly different from phenobarbital in the finding that phenobarbital lessened the survival ratio of CCl4-intoxicated mice, but gomisin A did not. Our observation suggest that gomisin A shows an antihepatotoxic action by oral application and also has hypolipidemic (mainly triglyceridemic) and liver protein synthesis-facilitating actions and that the enlargement of the liver seen with gomisin A is the adaptive hypertrophy which is due to the induction of drug-metabolizing enzymes.
Takeda
S
S
Maemura
S
S
Sudo
K
K
Kase
Y
Y
Arai
I
I
Ohkura
Y
Y
Funo
S
S
Fujii
Y
Y
Aburada
M
M
Hosoya
E
E
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury; D034242:Cyclooctanes; D004149:Dioxoles / Q000627:therapeutic use*; D005001:Ethionine / Q000037:antagonists & inhibitors; D005688:Galactosamine / Q000037:antagonists & inhibitors; D017705:Lignans; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects*; D006899:Mixed Function Oxygenases / Q000378:metabolism; D014176:Protein Biosynthesis; D051381:Rats; D011919:Rats, Inbred Strains; D012890:Sleep / Q000187:drug effects
D034242:Cyclooctanes; D004149:Dioxoles; D017705:Lignans; C033585:schizandrol B; D005688:Galactosamine; D006899:Mixed Function Oxygenases; D005001:Ethionine